Herlander Marques

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis

Sandra Fernandes Martins, Ricardo Amorim, Marta Viana‐Pereira et al. · BMC Cancer · 2016 · 66 citations · Full text

Medicine, Cancer Biology, Oncology +17

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

Julieta Afonso, Tatiana Pinto, Susana Simoes‐Sousa et al. · Cellular Oncology · 2019 · 66 citations · Full text

Medicine, Oncology, Pathology +17

FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients

Márcia Paiva, Herlander Marques, Ângelo Martins et al. · Cancer Genetics and Cytogenetics · 2008 · 42 citations

Life Sciences, Immunology, Oncology +12